Portal de Periódicos da CAPES

Immunotherapy for Type 1 Diabetes: Getting beyond a Negative First Impression

2012; Future Medicine; Volume: 4; Issue: 7 Linguagem: Inglês

10.2217/imt.12.54

1750-7448

Paolo Pozzilli, Rocky Strollo,

Diabetes Management and Research

ImmunotherapyVol. 4, No. 7 EditorialImmunotherapy for Type 1 diabetes: getting beyond a negative first impressionPaolo Pozzilli & Rocky StrolloPaolo Pozzilli* Author for correspondenceCentre of Diabetes, Blizard Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK. & Rocky StrolloDepartment of Endocrinology & Diabetes, University Campus Bio-Medico, Via Álvaro del Portillo, 21, 00128 Rome, ItalyPublished Online:1 Aug 2012https://doi.org/10.2217/imt.12.54AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: heterogeneityimmunotherapyType 1 diabetesReferences1 Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care26(3),832–836 (2003).Crossref, Medline, Google Scholar2 Ludvigsson J, Krisky D, Casas R et al. GAD65 antigen therapy in recently diagnosed Type 1 diabetes mellitus. N. Engl. J. Med.366(5),433–442 (2012).Crossref, Medline, CAS, Google Scholar3 Wherrett DK, Bundy B, Becker DJ et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset Type 1 diabetes: a randomised double-blind trial. Lancet378(9788),319–327 (2011).Crossref, Medline, CAS, Google Scholar4 Bielekova B, Goodwin B, Richert N et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a Phase II clinical trial with an altered peptide ligand. Nat. Med.6(10),1167–1175 (2000).Crossref, Medline, CAS, Google Scholar5 Sherry N, Hagopian W, Ludvigsson J et al. Teplizumab for treatment of Type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet378(9790),487–497 (2011).Crossref, Medline, CAS, Google Scholar6 Keymeulen B, Vandemeulebroucke E, Ziegler AG et al. Insulin needs after CD3-antibody therapy in new-onset Type 1 diabetes. N. Engl. J. Med.352(25),2598–2608 (2005).Crossref, Medline, CAS, Google Scholar7 Orban T, Bundy B, Becker DJ et al. Co-stimulation modulation with abatacept in patients with recent-onset Type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet378(9789),412–419 (2011).Crossref, Medline, CAS, Google Scholar8 Chatenoud L. Diabetes: Type 1 diabetes mellitus – a door opening to a real therapy? Nat. Rev. Endocrinol.7(10),564–566 (2011).Crossref, Medline, CAS, Google Scholar9 Buzzetti R, Cernea S, Petrone A et al. C-peptide response and HLA genotypes in subjects with recent-onset Type 1 diabetes after immunotherapy with DiaPep277: an exploratory study. Diabetes60(11),3067–3072 (2011).Crossref, Medline, CAS, Google Scholar10 Pozzilli P, Mesturino CA, Crino A, Gross TM, Jeng LM, Visalli N. Is the process of beta-cell destruction in Type 1 diabetes at time of diagnosis more extensive in females than in males? Eur. J. Endocrinol.145(6),757–761 (2001).Crossref, Medline, CAS, Google Scholar11 Lindholm E, Hallengren B, Agardh CD. Gender differences in GAD antibody-positive diabetes mellitus in relation to age at onset, C-peptide and other endocrine autoimmune diseases. Diabetes Metab. Res. Rev.20(2),158–164 (2004).Crossref, Medline, Google Scholar12 Shapira Y, Agmon-Levin N, Shoenfeld Y. Defining and analyzing geoepidemiology and human autoimmunity. J. Autoimmun.34(3),J168–J177 (2010).Crossref, Medline, CAS, Google Scholar101 GlaxoSmithKline: GlaxoSmithKline and Tolerx announce Phase III DEFEND-1 study of otelixizumab in Type 1 diabetes did not meet its primary end point. www.gsk.com/media/pressreleases/2011/2011_pressrelease_10039.htmGoogle Scholar102 Andromeda Biothech: Andromeda announces Phase III clinical study with DiaPep277®, a novel immunotherapeutic agent for Type 1 diabetes, met primary end point. www.andromedabio.com/page.php?pageID=6Google Scholar103 Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk". http://clinicaltrials.gov/ct2/show/NCT01030861?term=teplizumab&rank=1Google ScholarFiguresReferencesRelatedDetailsCited ByEffect of GLP‐1 and GIP on C‐peptide secretion after glucagon or mixed meal tests: Significance in assessing B‐cell function in diabetes9 May 2017 | Diabetes/Metabolism Research and Reviews, Vol. 33, No. 6Prevention of Type 1 Diabetes Mellitus21 July 2017New strategy for testing efficacy of immunotherapeutic compounds for diabetes in vitro10 May 2016 | BMC Biotechnology, Vol. 16, No. 1Prevention of Type 1 Diabetes Mellitus10 February 2016 Vol. 4, No. 7 STAY CONNECTED Metrics Downloaded 479 times History Published online 1 August 2012 Published in print July 2012 Information© Future Medicine LtdKeywordsheterogeneityimmunotherapyType 1 diabetesFinancial & competing interests disclosureP Pozzilli has been principal investigator in trials testing otelixizumab (GSK-Tolerx), GAD vaccine (Diamyd Medical) and DiaPep277 (Andromeda Biotech). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download